NORINYL 1+35 28-DAY
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+35 is an oral contraceptive tablet containing norethindrone and ethinyl estradiol in a 28-day cycle formulation. It prevents pregnancy through hormonal suppression of ovulation and cervical mucus thickening. This is a foundational combined oral contraceptive product in the women's health market.
LOE Approaching
Mature product in advanced lifecycle stage with moderate competitive pressure (30 intensity score); expect focused brand defense rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORINYL 1+35 offers stability in a mature, well-established franchise but limited growth trajectory in a crowded market. Roles focus on brand defense, market access, and operational efficiency rather than innovation, making this suitable for professionals seeking stable portfolio stewardship over high-visibility launches.
Brand ManagerField Sales Representative
Worked on NORINYL 1+35 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.